Display options
Cite
Gitt AK, Lautsch D, Ferrières J, et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data Brief. 2018;18:1937-1940doi: 10.1016/j.dib.2018.04.092.
Gitt, A. K., Lautsch, D., Ferrières, J., De Ferrari, G. M., Vyas, A., Baxter, C. A., Bash, L. D., Ashton, V., Horack, M., Almahmeed, W., Chiang, F. T., Poh, K. K., Brudi, P., & Ambegaonkar, B. (2018). Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in brief, 181937-1940. https://doi.org/10.1016/j.dib.2018.04.092
Gitt, Anselm K, et al. "Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world." Data in brief vol. 18 (2018): 1937-1940. doi: https://doi.org/10.1016/j.dib.2018.04.092
Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data Brief. 2018 May 01;18:1937-1940. doi: 10.1016/j.dib.2018.04.092. eCollection 2018 Jun. PMID: 29904698; PMCID: PMC5998213.
Copy Download .nbib Format: NLM
Share it on

Data Brief. 2018 May 01;18:1937-1940. doi: 10.1016/j.dib.2018.04.092. eCollection 2018 Jun.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world.

Data in brief

Anselm K Gitt, Dominik Lautsch, Jean Ferrières, Gaetano M De Ferrari, Ami Vyas, Carl A Baxter, Lori D Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu-Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar

Affiliations

  1. Herzzentrum Ludwigshafen, Germany.
  2. Institut für Herzinfarktforschung, Ludwigshafen, Germany.
  3. Merck&Co, Inc., Kenilworth, NJ, USA.
  4. Rangueil hospital, Toulouse university school of medicine, Toulouse, France.
  5. Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
  6. Rutgers University, School of Public Health, Piscataway, NJ, USA.
  7. Merck Sharp & Dohme, Corp., Hertford Road, Hoddesdon, UK.
  8. Agile-1 for Merck & Co., Inc., Kenilworth, NJ, USA.
  9. Sheikh Khalifa Medical City, Abu Dhabi, UAE.
  10. Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, UAE.
  11. National Taiwan University Hospital, Taipei, Taiwan.
  12. Fu-Jen Catholic University Hospital, Taipei, Taiwan.
  13. Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  14. Department of Cardiology, National University Heart Center Singapore, National University Health System, Singapore.

PMID: 29904698 PMCID: PMC5998213 DOI: 10.1016/j.dib.2018.04.092

Abstract

DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin. The mean low-density lipoprotein cholesterol (LDL-C) level was 88 mg/dL, with 29.4% of patients displaying a level below the 70 mg/dL target for very high-risk subjects.

CONCLUSION: While more than 90% of patients with CHD were on lipid lowering drugs, only three out of ten patients achieved their LDL-C target value.

Keywords: Global; Low-density lipoprotein cholesterol; Region; Statins; Treatment target

References

  1. J Clin Pharm Ther. 2010 Apr;35(2):139-51 - PubMed
  2. Eur Heart J. 2011 Jul;32(14):1769-818 - PubMed
  3. Atherosclerosis. 2017 Nov;266:158-166 - PubMed

Publication Types